Back to Search
Start Over
Glutamate-based antidepressants: preclinical psychopharmacology.
- Source :
-
Biological psychiatry [Biol Psychiatry] 2013 Jun 15; Vol. 73 (12), pp. 1125-32. Date of Electronic Publication: 2013 Feb 28. - Publication Year :
- 2013
-
Abstract
- Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the N-methyl-D-aspartate receptor antagonists ketamine and traxoprodil provide target validation for this family of ionotropic glutamate receptors. This article reviews the preclinical evidence that it may be possible to develop glutamate-based antidepressants by not only modulating ionotropic (N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) and metabotropic glutamate (mGlu) receptors, including mGlu2/3, mGLu5 and mGlu7 receptors, but also by altering synaptic concentrations of glutamate via specialized transporters such as glial glutamate transporter 1 (excitatory amino-acid transporter 2).<br /> (Copyright © 2013 Society of Biological Psychiatry. All rights reserved.)
- Subjects :
- Animals
Antidepressive Agents pharmacology
Excitatory Amino Acid Antagonists pharmacology
Excitatory Amino Acid Antagonists therapeutic use
Glutamic Acid metabolism
Humans
Antidepressive Agents therapeutic use
Depressive Disorder drug therapy
Drug Evaluation, Preclinical
Psychopharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2402
- Volume :
- 73
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Biological psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 23453290
- Full Text :
- https://doi.org/10.1016/j.biopsych.2013.01.021